Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records

Non-Hematologic Malignancy Clinical Trial

Official title:

Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records (GRECO)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03625557
• Other study ID #: 01-MX-002
• Status: Completed
• Start date: April 30, 2019
• Est. completion date: April 16, 2020

Study information

• Verified date: April 2020
• Source: Guardant Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To document the clinical outcomes of cancer patients who received the Guardant360® test and agree to share their records with Guardant Health.

Description:

This is an observational study of clinical outcomes to be conducted in the United States. Patients with a diagnosis of Stage 3-4 advanced cancer who possess specific pathway mutations identified by the Guardant360® test will be eligible to enroll in the study. Patients will be recruited by telephone or email and/or through the Guardant Health Patient Portal to determine interest in the study. Should patients be interested in contributing to this registry study, they will be prompted to consent via a commercial service for patients to request, manage, and view their medical records. Enrolled participants will be requested to release copies of their medical records for review by the principal investigator. Study adminsitrators will abstract participant demographics, cancer-related therapies, and clinical outcomes for analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: April 16, 2020
• Est. primary completion date: February 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

General Inclusion Criteria:

• Adults (= 18 years old) with a diagnosis of Stage 3 or Stage 4 cancer (non-hematologic malignancy). Patients with advanced cancers not typically staged 1-4 (such as extensive stage small lung cancer) may be enrolled.

• Results from Guardant360® test

• Patient has previously provided contact information (either email or phone) to Guardant Health.

• Able and wiling to complete the informed consent process.

• Willingness to consent to the release of medical records.

• Willingness to provide Medical Records Release

General Exclusion Criteria:

• Unwilling or unable to provide written informed consent.

• Unable to understand English.

• Diagnosis of NSCLC

• Guardant 360® test results released to the patient's physician no less than 14 days and no greater than 60 days prior to initial patient contact.

Related Conditions & MeSH terms

• Neoplasms
• Non-Hematologic Malignancy

Locations

Country	Name	City	State
United States	Guardant Health	Redwood City	California

Sponsors (1)

Lead Sponsor	Collaborator
Guardant Health, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR)	Portion of patients with tumors that are found to have complete or partial response	3 years